Table 2.
Primary efficacy and other endpoints n (%)
| Outcome | BIS + 2-L PEG-CS (n = 138) | 4-L PEG (n = 126) | P value |
| Bowel cleansing | |||
| A (all segments as excellent or good) | 107 (77.5) | 105 (83.3) | NS |
| B (at least one segment as fair) | 21 (15.2) | 11 (8.7) | |
| C (at least one segment as poor) | 7 (5.1) | 8 (6.3) | |
| D (exam not completed) | 3 (2.2) | 2 (1.6) | |
| Successful (A + B) | 128 (92.8) | 116 (92.1) | NS |
| Unsuccessful (C + D) | 10 (7.2) | 10 (7.9) | |
| Tolerability | |||
| Nausea | 27 (19.6) | 26 (20.6) | 0.575 |
| Bloating | 11 (8.0) | 33 (26.2) | < 0.001 |
| Abdominal discomfort | 13 (9.4) | 5 (4.0) | 0.079 |
| Overall (any of previous ones) | 45 (32.6) | 57 (45.2) | 0.035 |
| Acceptance | |||
| Good | 70 (50.7) | 30 (23.8) | < 0.001 |
| Satisfactory | 55 (39.9) | 67 (53.2) | |
| Not acceptable | 13 (9.4) | 22 (23.0) | |
| Compliance | |||
| 100% of solution drunk | 134 (97.1) | 110 (87.3) | 0.010 |
| 75% of solution drunk | 4 (2.9) | 15 (11.9) | |
| 50% or less of solution drunk | 0 (0.0) | 1 (0.8) |
PEG: Polyethylene glycol; PEG-CS: PEG with citrates and simethicone; BIS: Bisacodyl.